CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Inclusion Criteria

• •Histologically confirmed recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer after second-line therapy
• •* Received 1 prior platinum-based first-line chemotherapy regimen and 1 prior second-line (non-platinum, non-taxane) chemotherapy regimen
• •At least 1 unidimensionally measurable lesion
• •* At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
• •* At least 1 target lesion that has not previously been irradiated
• •Ineligible for a higher priority GOG protocol (if one exists)
• •Ineligible for the currently active phase II cytotoxic protocol for platinum-resistant disease
• •Performance status - GOG 0-2
• •Absolute neutrophil count at least 1,500/mm\^3
• •Platelet count at least 100,000/mm\^3
• •No active bleeding
• •Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• •SGOT no greater than 2.5 times ULN
• •Alkaline phosphatase no greater than 2.5 times ULN
• •PT or PTT less than ULN
• •Creatinine no greater than 1.5 times ULN
• •No uncontrolled hypertension
• •No uncompensated congestive heart failure
• •No symptomatic coronary artery disease
• •No myocardial infarction within the past 6 months
• •No sensory or motor neuropathy greater than grade 1
• •No active infection requiring antibiotics
• •No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •At least 3 weeks since prior biological therapy or immunotherapy directed at the malignancy
• •No prior polyglutamate paclitaxel (CT-2103)
• •Recovered from prior chemotherapy
• •At least 1 week since prior hormonal therapy directed at the malignancy
• •Concurrent hormone replacement therapy allowed
• •Recovered from prior radiotherapy
• •No prior radiotherapy to more than 25% of bone marrow
• •Recovered from prior surgery
• •At least 3 weeks since other prior therapy directed at the malignancy
• •No prior therapy for another malignancy that would preclude this study
• •No concurrent amifostine or other protective reagents